12 Health Care Stocks Moving In Friday's After-Market Session

Akanda Corp
Akari Therapeutics Plc Sponsored ADR
Artelo Biosciences Inc
Femasys, Inc.
Galectin Therapeutics Inc.

Akanda Corp

AKAN

0.00

Akari Therapeutics Plc Sponsored ADR

AKTX

0.00

Artelo Biosciences Inc

ARTL

0.00

Femasys, Inc.

FEMY

0.00

Galectin Therapeutics Inc.

GALT

0.00

Gainers

  • Artelo Biosciences (NASDAQ:ARTL) stock rose 70.6% to $2.03 during Friday's after-market session. The market value of their outstanding shares is at $2.9 million.
  • Stablecoin Development (AMEX:SDEV) stock increased by 17.73% to $1.66. The market value of their outstanding shares is at $39.4 million.
  • Femasys (NASDAQ:FEMY) shares moved upwards by 16.94% to $0.51. The market value of their outstanding shares is at $20.3 million.
  • QTREX Quantum (NASDAQ:QTEX) shares increased by 14.14% to $0.83.
  • Galectin Therapeutics (NASDAQ:GALT) shares increased by 9.8% to $2.75. The company's market cap stands at $165.9 million.
  • Intelligent Bio Solutions (NASDAQ:INBS) stock increased by 7.0% to $2.75. The market value of their outstanding shares is at $6.2 million.

Losers

  • rYojbaba (NASDAQ:RYOJ) stock fell 27.8% to $3.61 during Friday's after-market session. The company's market cap stands at $22.6 million.
  • Akari Therapeutics (NASDAQ:AKTX) shares declined by 20.36% to $14.55. The company's market cap stands at $183.7 million. As per the news, the Q1 earnings report came out 3 days ago.
  • Akanda (NASDAQ:AKAN) shares decreased by 12.21% to $23.81. The company's market cap stands at $12.5 million.
  • XTL Biopharmaceuticals (NASDAQ:XTLB) shares declined by 9.17% to $2.28. The company's market cap stands at $23.5 million.
  • Purple Biotech (NASDAQ:PPBT) shares declined by 7.99% to $2.65. The company's market cap stands at $2.5 million.
  • Odyssey Therapeutics (NASDAQ:ODTX) stock declined by 7.36% to $16.21. The market value of their outstanding shares is at $836.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.